Eric B Haura

Summary

Affiliation: University of South Florida
Country: USA

Publications

  1. ncbi request reprint Management of advanced non-small cell lung cancer: current trends
    Eric B Haura
    Thoracic Oncology Program and Clinical Investigations Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Curr Opin Pulm Med 8:251-6. 2002
  2. ncbi request reprint Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer
    Eric B Haura
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Nat Clin Pract Oncol 2:315-24. 2005
  3. ncbi request reprint Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer
    Eric B Haura
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Clin Lung Cancer 7:273-5. 2006
  4. pmc Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors
    Justin M Balko
    Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536 0082, USA
    BMC Genomics 7:289. 2006
  5. ncbi request reprint Is repetitive wounding and bone marrow-derived stem cell mediated-repair an etiology of lung cancer development and dissemination?
    Eric B Haura
    The H Lee Moffitt Cancer Center and Research Institute, Department of Interdisciplinary Oncology, University of South Florida College of Medicine, MRC3 East, Tampa, FL 33612 9497, United States
    Med Hypotheses 67:951-6. 2006
  6. ncbi request reprint Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies
    Eric B Haura
    Thoracic Oncology and Experimental Therapeutics Programs, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Clin Lung Cancer 6:113-22. 2004
  7. ncbi request reprint SRC and STAT pathways
    Eric B Haura
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    J Thorac Oncol 1:403-5. 2006
  8. pmc Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
    Jiannong Li
    Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Mol Syst Biol 9:705. 2013
  9. pmc Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells
    Jingchun Gao
    Department of Experimental Therapeutics and Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    Cancer Biol Ther 8:1671-9. 2009
  10. doi request reprint Src kinases as therapeutic targets for cancer
    Lori C Kim
    University of South Florida College of Medicine, Tampa, FL, USA
    Nat Rev Clin Oncol 6:587-95. 2009

Research Grants

Collaborators

Detail Information

Publications55

  1. ncbi request reprint Management of advanced non-small cell lung cancer: current trends
    Eric B Haura
    Thoracic Oncology Program and Clinical Investigations Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Curr Opin Pulm Med 8:251-6. 2002
    ..These include further work on combination chemotherapy, the introduction of novel biologic agents into treatment, and predicting which patients will respond to chemotherapy. These trends are discussed in this review...
  2. ncbi request reprint Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer
    Eric B Haura
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Nat Clin Pract Oncol 2:315-24. 2005
    ..This review will highlight STAT signaling pathways, STAT target genes involved in cancer, evidence for STAT activation in human cancers, and therapeutic strategies to target STAT molecules for anticancer therapy...
  3. ncbi request reprint Autocrine interleukin-6/interleukin-6 receptor stimulation in non-small-cell lung cancer
    Eric B Haura
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Clin Lung Cancer 7:273-5. 2006
    ..These results suggest that IL-6 autocrine signaling might contribute to downstream signaling events in NSCLC and further support the concept of multiple autocrine pathways contributing to the pathogenesis of NSCLC...
  4. pmc Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors
    Justin M Balko
    Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536 0082, USA
    BMC Genomics 7:289. 2006
    ..Furthermore, we anticipated that this methodology would result in improved predictions compared to single parameters alone both in vitro and in vivo...
  5. ncbi request reprint Is repetitive wounding and bone marrow-derived stem cell mediated-repair an etiology of lung cancer development and dissemination?
    Eric B Haura
    The H Lee Moffitt Cancer Center and Research Institute, Department of Interdisciplinary Oncology, University of South Florida College of Medicine, MRC3 East, Tampa, FL 33612 9497, United States
    Med Hypotheses 67:951-6. 2006
    ..Finally, a bone marrow derived lung cancer stem cell would require stem cell poisons for cure...
  6. ncbi request reprint Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies
    Eric B Haura
    Thoracic Oncology and Experimental Therapeutics Programs, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Clin Lung Cancer 6:113-22. 2004
    ....
  7. ncbi request reprint SRC and STAT pathways
    Eric B Haura
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    J Thorac Oncol 1:403-5. 2006
  8. pmc Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
    Jiannong Li
    Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Mol Syst Biol 9:705. 2013
    ..Our results, enabled by interactome mapping, suggest new targets and combination therapies that could circumvent EGFR TKI resistance. ..
  9. pmc Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells
    Jingchun Gao
    Department of Experimental Therapeutics and Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    Cancer Biol Ther 8:1671-9. 2009
    ..These results suggest that Mirk is overexpressed in lung cancer, acts as a survival factor in lung cancer cells and may be a novel therapeutic target...
  10. doi request reprint Src kinases as therapeutic targets for cancer
    Lori C Kim
    University of South Florida College of Medicine, Tampa, FL, USA
    Nat Rev Clin Oncol 6:587-95. 2009
    ..In preclinical studies these agents can suppress tumor growth and metastases. The agents seem to be safe in humans and could add to the therapeutic arsenal against subsets of cancers...
  11. ncbi request reprint Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer
    Eric B Haura
    Thoracic Oncology Program and Biostatistics Core, The H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    Clin Cancer Res 11:8288-94. 2005
    ..We evaluated Stat3 activation in early stage non-small cell lung cancers (NSCLC) and how this relates to upstream epidermal growth factor receptor (EGFR) activation, tumor apoptosis, and prognosis...
  12. pmc A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
    Jiannong Li
    Department of Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Nat Chem Biol 6:291-9. 2010
    ..The combined mass spectrometry-based approach described here provides a system-level view of dasatinib action in cancer cells and suggests both functional targets and a rationale for combinatorial therapeutic strategies...
  13. ncbi request reprint A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance
    Eric B Haura
    Department of Thoracic Oncology, The H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9497, USA
    J Thorac Oncol 5:1806-14. 2010
    ..To explore these questions, we conducted a trial of a brief course of preoperative gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, in early-stage non-small cell lung cancer...
  14. doi request reprint Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors
    Yun Bai
    Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Res 72:2501-11. 2012
    ..Together, our findings suggest that integrating global phosphoproteomics with functional analyses with kinase inhibitors can identify drivers of sarcoma growth and survival...
  15. ncbi request reprint A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells
    Jiannong Li
    Thoracic Oncology and Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, MRC3 East, Tampa, FL 33612 9497, USA
    Cancer Chemother Pharmacol 61:525-34. 2008
    ..Non-small cell lung cancer (NSCLC) cells are typically resistant to cytotoxic chemotherapy and approaches that alter the balance between pro-survival and pro-death Bcl-2 family members have shown promise in preclinical models of NSCLC...
  16. ncbi request reprint Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells
    Lanxi Song
    Thoracic Oncology Experimental Therapeutics, University of South Florida College of Medicine, Tampa, Florida, USA
    Cancer Biol Ther 4:267-76. 2005
    ..Mcl-1 protein is overexpressed in a subset of human NSCLC and enhanced levels of Mcl-1 may protect lung cancer cells from death induced by a variety of pro-apoptotic stimuli...
  17. pmc Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer
    Eric B Haura
    Department of Thoracic Oncology and Biostatistics, Clinical Trials and Clinical Pharmacology Core, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    J Clin Oncol 28:1387-94. 2010
    ....
  18. ncbi request reprint Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells
    Lanxi Song
    Experimental Therapeutics, H Lee Moffitt Cancer Center and Research Insitute, University of South Florida College of Medicine Tampa, FL 33612, USA
    Oncogene 22:4150-65. 2003
    ..These results demonstrate a role of Stat3 in transducing survival signals downstream of tyrosine kinases such as Src, EGF-R, and c-Met, as well as cytokines such as IL-6, in human nonsmall cell lung cancers...
  19. ncbi request reprint MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion
    Jingchun Gao
    Department of Thoracic Oncology and Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Int J Oncol 35:337-45. 2009
    ..MUC1 appears to be a cooperating oncoprotein with multiple oncogenic tyrosine kinase pathways and could be an effective target for the treatment of lung cancer...
  20. pmc Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling
    Bin Fang
    Proteomics, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Biochem Pharmacol 80:739-47. 2010
    ..In this review, commonly applied technologies and workflows are discussed to illustrate the role of proteomics in examining tumor biology and therapeutic intervention using kinase inhibitors...
  21. pmc Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions
    Lu Chen
    Molecular Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Biol Chem 287:40106-18. 2012
    ..Trim28 appears up-regulated in many cancers...
  22. pmc Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer
    Dung Tsa Chen
    Department of Biostatistics, Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Natl Cancer Inst 103:1859-70. 2011
    ..We hypothesized that the malignancy-risk gene signature has prognostic and predictive value for early-stage non-small cell lung cancer (NSCLC) patients...
  23. ncbi request reprint Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells
    Arthur Edwards
    Thoracic Oncology and Experimental Therapeutics Programs, H Lee Moffitt Cancer Center and Research Institute, MRC3 East, Room 3056, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    Mol Cancer Ther 6:2515-24. 2007
    ..Therefore, EGFR mutation status may be predictive of outcome with LBH589 and possibly other HDACi...
  24. ncbi request reprint Stat3 regulates genes common to both wound healing and cancer
    Daniel J Dauer
    Thoracic Oncology Experimental Therapeutics, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Oncogene 24:3397-408. 2005
    ..These findings provide a molecular basis for understanding cancer as a deregulation of normal wound healing processes...
  25. pmc TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells
    Sarah S Donatelli
    Departments of Immunology, Molecular Oncology, Thoracic Oncology, Cancer Epidemiology, and Anatomic Pathology, Moffitt Cancer Center, Tampa, FL 33612
    Proc Natl Acad Sci U S A 111:4203-8. 2014
    ..Moreover, we documented reduced DAP12 expression in tumor-associated NK cells in lung cancer patients, illustrating this pathway to be consistently perturbed in the human tumor microenvironment. ..
  26. ncbi request reprint EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer
    Bernadette Ferraro
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, MRC3 E, Room 3056, 12902 Magnolia Dr, Tampa, FL 33612 9497, USA
    J Clin Oncol 23:1921-6. 2005
    ..For these reasons, we hypothesized that reduced levels of EGR1 would correlate with inferior outcome in patients with NSCLC...
  27. ncbi request reprint Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer
    Zhong Zheng
    Thoracic Oncology Program, The H Lee Moffitt Cancer Center and Research Institute, MRC3 East, Room 3056, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    Chest 128:308-16. 2005
    ..We also hypothesized that EGFR activity may be prognostic for early-stage NSCLC...
  28. doi request reprint Dasatinib in solid tumors
    Lori C Kim
    University of South Florida College of Medicine, 12902 Magnolia Drive, MCC GME, Tampa, Florida 33612, USA
    Expert Opin Investig Drugs 19:415-25. 2010
    ..However, dasatinib is also being explored in solid tumors in ongoing Phase I and II clinical trials...
  29. ncbi request reprint Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival
    Lanxi Song
    Thoracic Oncology and Experimental Therapeutics and Molecular Oncology Programs, H Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, Florida, USA
    Cancer Res 66:5542-8. 2006
    ..Our results suggest EGFR status is important in deciding cell fate in response to dasatinib...
  30. ncbi request reprint Effects of IFN-gamma and Stat1 on gene expression, growth, and survival in non-small cell lung cancer cells
    Jiannong Li
    Thoracic Oncology Experimental Therapeutics, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Interferon Cytokine Res 27:209-20. 2007
    ..These results suggest the major role of IFN-gamma and Stat1 in lung cells is to direct a proinflammatory gene expression program rather than have major effects on cell growth or survival or both...
  31. doi request reprint Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older
    George R Simon
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer 112:2021-9. 2008
    ..The primary endpoint was response rate (RR). Secondary endpoints were overall survival (OS) and progression-free survival (PFS)...
  32. pmc Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance
    Emily L Hopewell
    Department of Immunology, Moffitt Cancer Center, Tampa, Florida 33612, USA
    J Clin Invest 123:2509-22. 2013
    ..These results therefore indicate that NF-κB activity mediates immune surveillance and promotes antitumor T cell responses in both murine and human lung cancer...
  33. ncbi request reprint Gene therapy for lung cancer
    Eric B Haura
    Thoracic Oncology Program, The H Lee Moffitt Cancer Center and Research Institute MRC3 East, Room 3056, 12902 Magnolia Drive, Tampa, FL 33612 9497, USA
    Mol Biotechnol 25:139-48. 2003
    ..Nonetheless, these approaches are likely to yield important biologic and clinical data which will further the progress of lung cancer treatment...
  34. pmc Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells
    Jae Young Kim
    Department ofThoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Proc Natl Acad Sci U S A 110:12414-9. 2013
    ..These results collectively revealed TBK1 as a mitosis regulator through activation of PLK1 and also suggested metadherin as a putative TBK1 downstream effector involved in lung cancer cell survival. ..
  35. ncbi request reprint Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature
    Gina D'Amato
    Experimental Therapeutics and Thoracic Oncology Programs, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    Lung Cancer 44:381-90. 2004
    ..Given the increased use of docetaxel and other taxanes in the treatment of advanced lung cancer, physicians should be aware of this potential toxicity of therapy...
  36. pmc A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors
    George R Simon
    H Lee Moffitt Cancer Center, Tampa, FL, USA
    Cancer Chemother Pharmacol 68:1233-41. 2011
    ..This phase I study was carried out to determine the phase II recommended dose of tasisulam sodium (hereafter, tasisulam), a novel anticancer agent with a unique mechanism of action...
  37. pmc GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells
    Lily L Remsing Rix
    Department of Drug Discovery, Department of Thoracic Oncology, and Molecular Oncology and Proteomics, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9497, United States
    ACS Chem Biol 9:353-8. 2014
    ..In summary, GSK3α and GSK3β are new kinase targets of tivantinib that play an important role in its cellular mechanism-of-action in NSCLC. ..
  38. pmc Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer
    Mark G Alexandrow
    Department of Molecular Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, Florida 33612, USA
    Eur J Cancer Prev 21:407-12. 2012
    ..These data provide a rationale for the use of curcumin as a promising chemopreventive agent in high-risk populations such as former smokers...
  39. doi request reprint Targeting epidermal growth factor receptor: central signaling kinase in lung cancer
    Takeshi Yoshida
    Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive Tampa, FL 33612, USA
    Biochem Pharmacol 80:613-23. 2010
    ....
  40. ncbi request reprint Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1
    Yihong Ma
    Experimental Therapeutics Programs, H Lee Moffitt Cancer Center and Research Institute, and Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, Florida 33612, USA
    Mol Cancer Ther 2:73-81. 2003
    ..These data suggest that apoptosis induced by flavopiridol is dependent on the enhancement of E2F1 levels and the repression of Mcl-1...
  41. ncbi request reprint Molecular origins of lung cancer: prospects for personalized prevention and therapy
    Eric B Haura
    Department of Thoracic Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USA
    J Thorac Oncol 5:S207-13. 2010
    ..This includes molecular based strategies not only for treatment of established cancers but also individualized and molecularly-based strategies for cancer risk reduction and chemoprevention...
  42. pmc Proteomic contributions to personalized cancer care
    John M Koomen
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
    Mol Cell Proteomics 7:1780-94. 2008
    ....
  43. pmc Healthcare providers' knowledge and attitudes about rapid tissue donation (RTD): phase one of establishing a rapid tissue donation programme in thoracic oncology
    Matthew B Schabath
    Department of Cancer Epidemiology, H Lee Moffitt Cancer and Research Institute, Tampa, Florida, USA
    J Med Ethics 40:139-42. 2014
    ..Our study provides important information about characteristics associated with low levels of knowledge and practice related to RTD where additional education and training may be warranted. ..
  44. doi request reprint Non-canonical IKKs, IKKϵ and TBK1, as novel therapeutic targets in the treatment of non-small cell lung cancer
    Jae Young Kim
    H Lee Moffitt Cancer Center and Research Institute, Department of Thoracic Oncology and Chemical Biology and Molecular Medicine Program, 12902 Magnolia Dr Tampa, FL 33612, USA
    Expert Opin Ther Targets 17:1109-12. 2013
    ..This article will briefly describe signaling pathways mediated by these non-canonical IKKs, especially focusing in lung cancer, and discuss their potential as molecular targets for lung cancer treatment. ..
  45. ncbi request reprint The potential benefits of BIM in the further pursuit of biomarker discovery in cancer therapeutics
    Takeshi Yoshida
    Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Discov 1:289-90. 2011
    ..Their results suggest that pre-treatment assessment of BIM levels can identify patients who would benefit from molecularly targeted therapies even after biomarker-based patient selection...
  46. pmc From modules to medicine: How modular domains and their associated networks can enable personalized medicine
    Eric B Haura
    Department of Thoracic Oncology Program and Experimental Therapeutics Program, The H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    FEBS Lett 586:2580-5. 2012
    ....
  47. doi request reprint A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer
    Eric B Haura
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Clin Cancer Res 16:2450-7. 2010
    ....
  48. pmc Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer
    Lanxi Song
    Department of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Janssen R and D, Spring House, PA Department of Anatomic Pathology and Department of Biostatistics, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
    J Thorac Oncol 9:974-82. 2014
    ..We examined IL-6/STAT3 in lung cancer tumor tissues and the effects of siltuximab, a neutralizing antibody to human IL-6, in mouse models of lung cancer...
  49. pmc The NAD+ synthesis enzyme nicotinamide mononucleotide adenylyltransferase (NMNAT1) regulates ribosomal RNA transcription
    Tanjing Song
    Department of Molecular Oncology, Moffitt Cancer Center, Tampa, Florida 33612, USA
    J Biol Chem 288:20908-17. 2013
    ..These results suggest that NMNAT1 deletion in tumors may contribute to transformation by increasing rRNA synthesis, but may also increase sensitivity to nutrient stress and DNA damage. ..
  50. doi request reprint Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer
    Alberto Chiappori
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida Arlington Cancer Center, Arlington, Texas Mayo Clinic Arizona, Scottsdale, Arizona Georgetown University Hospital, Washington, District of Columbia University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland Tower Cancer Research Foundation, Beverly Hills, California MedStar Research Institute, Hyattsville, Maryland and formerly Gemin X Pharmaceuticals, an indirect wholly owned subsidiary of Teva Pharmaceutical Industries Ltd, Petach Tikva, Israel
    J Thorac Oncol 9:121-5. 2014
    ..The proapoptotic small-molecule pan-Bcl-2 inhibitor obatoclax mesylate (GX15-070) may enhance the cytotoxicity of chemotherapy in relapsed/refractory non-small-cell lung cancer (NSCLC)...
  51. pmc Stakeholder perceptions of thoracic rapid tissue donation: An exploratory study
    Jessica McIntyre
    Cancer Prevention and Control, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Soc Sci Med 99:35-41. 2013
    ..Our approach of querying all stakeholders provides a firm foundation for future training modules regarding RTD programs in lung cancer. ..
  52. doi request reprint Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors
    Rongshi Li
    Department of Drug Discovery, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612, USA
    J Med Chem 55:2474-8. 2012
    ..Compounds 18 and 24 inhibited potently the phosphorylation of the ROCK substrate MLC2 in intact human breast cancer cells...
  53. ncbi request reprint Gene therapy for lung cancer. An introduction
    Eric B Haura
    H Lee Moffitt Cancer Center, Tampa, FL, USA
    Methods Mol Med 75:529-43. 2003
    ..However, it is very likely that these pioneering clinical trials will provide important clinical and immunological information that will be the basis for future attempts to effectively harness the immune system against lung cancer...
  54. doi request reprint IPEP: an in silico tool to examine proteolytic peptides for mass spectrometry
    Dihui Lu
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Bioinformatics 24:2801-2. 2008
    ..The iPEP tool can assist with experimental design by maximizing the detection of proteins, consensus sites and modified residues of interest for individual proteins or as part of large-scale proteomic assays...
  55. ncbi request reprint Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer
    Carme Sarries
    Medical Oncology Service, Hospital Germans Trias i Pujol, Barcelona, Spain
    Pharmacogenomics 3:763-80. 2002
    ..Hopefully, the assessment of Src and of STAT-3 can be implemented as predictive markers...

Research Grants2

  1. Stat3 in EGFR Driven Non-Small Cell Lung Cancer
    Eric Haura; Fiscal Year: 2007
    ..mutant EGFR proteins, (2) to characterize the role of Stat3 in regulating proliferation and survival of EGFR-dependent NSCLC, and (3) to evaluate the effects of gefitinib on EGFR-Stat3 signaling in vivo in a prospective clinical trial ..
  2. Antitumor Mechanisms of SRC Inhibitors in Lung Cancer
    Eric Haura; Fiscal Year: 2007
    ....